NicVax: Preliminary Phase II data

Preliminary data from a double-blind, Dutch Phase II trial in 558 patients showed that NicVax plus Chantix varenicline missed the primary endpoint of improving abstinence rate at 12 months as measured from week 9 through week 52 using self-reported cigarette consumption and exhaled carbon dioxide vs. placebo plus Chantix. Last year, NicVax missed the primary endpoint of abstinence rate vs. placebo in a pair of Phase III trials (see BioCentury, July 25, 2011 & Nov. 14, 2011). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Chantix for smoking cessation. ...